Cancer Genetics Inc (NASDAQ:CGIX) Given Average Rating of “Strong Buy” by Brokerages
Posted by Wayne Rhoads on Jan 18th, 2016 // No Comments
Cancer Genetics logoShares of Cancer Genetics Inc (NASDAQ:CGIX) have received an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Analysts have set a twelve-month consensus price objective of $7.00 for the company and are predicting that the company will post ($0.46) EPS for the current quarter, according to Zacks. Zacks has also assigned Cancer Genetics an industry rank of 15 out of 265 based on the ratings given to its competitors.
A number of equities analysts have weighed in on CGIX shares. Aegis reissued a “positive” rating on shares of Cancer Genetics in a research report on Tuesday, October 6th. Zacks Investment Research upgraded Cancer Genetics from a “hold” rating to a “strong-buy” rating and set a $9.00 price objective for the company in a report on Tuesday, October 13th.
Shares of Cancer Genetics (NASDAQ:CGIX) opened at 2.24 on Wednesday. The company’s 50-day moving average price is $2.96 and its 200-day moving average price is $7.20. Cancer Genetics has a 12-month low of $1.90 and a 12-month high of $12.75. The firm’s market capitalization is $23.86 million.
Cancer Genetics (NASDAQ:CGIX) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by $0.07. During the same quarter in the previous year, the business posted ($0.51) earnings per share. The business earned $4 million during the quarter, compared to analysts’ expectations of $5.13 million. The firm’s revenue was up 25.0% on a year-over-year basis. Analysts anticipate that Cancer Genetics will post ($1.94) EPS for the current year.
